295 related articles for article (PubMed ID: 35215980)
1. A Perspective on the Roles of Adjuvants in Developing Highly Potent COVID-19 Vaccines.
Zhang N; Li K; Liu Z; Nandakumar KS; Jiang S
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215980
[TBL] [Abstract][Full Text] [Related]
2. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
3. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus.
Dillard JA; Taft-Benz SA; Knight AC; Anderson EJ; Pressey KD; Parotti B; Martinez SA; Diaz JL; Sarkar S; Madden EA; De la Cruz G; Adams LE; Dinnon KH; Leist SR; Martinez DR; Schäfer A; Powers JM; Yount BL; Castillo IN; Morales NL; Burdick J; Evangelista MKD; Ralph LM; Pankow NC; Linnertz CL; Lakshmanane P; Montgomery SA; Ferris MT; Baric RS; Baxter VK; Heise MT
Nat Commun; 2024 May; 15(1):3738. PubMed ID: 38702297
[TBL] [Abstract][Full Text] [Related]
5. Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.
Zhou X; Wang H; Ji Q; Du M; Liang Y; Li H; Li F; Shang H; Zhu X; Wang W; Jiang L; Stepanov AV; Ma T; Gong N; Jia X; Gabibov AG; Lou Z; Lu Y; Guo Y; Zhang H; Yang X
Protein Cell; 2021 Oct; 12(10):818-823. PubMed ID: 33909239
[No Abstract] [Full Text] [Related]
6. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Immunogenicity of Alum and MF59-Like Adjuvant Inactivated SARS-CoV-2 Vaccines Against SARS-CoV-2 Variants in Elderly Mice.
Bai S; Kang Y; Chen W; Xie H; Zhang L; Lv M; Wang J; Wu J; Zhao W
Viral Immunol; 2023 Oct; 36(8):526-533. PubMed ID: 37625037
[TBL] [Abstract][Full Text] [Related]
8. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
9. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
Sharma O; Sultan AA; Ding H; Triggle CR
Front Immunol; 2020; 11():585354. PubMed ID: 33163000
[TBL] [Abstract][Full Text] [Related]
10. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
11. Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice.
Song S; Zhou B; Cheng L; Liu W; Fan Q; Ge X; Peng H; Fu YX; Ju B; Zhang Z
Virol J; 2022 Jan; 19(1):2. PubMed ID: 34983583
[TBL] [Abstract][Full Text] [Related]
12. A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.
Steinbuck MP; Seenappa LM; Jakubowski A; McNeil LK; Haqq CM; DeMuth PC
Sci Adv; 2021 Feb; 7(6):. PubMed ID: 33547083
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.
King HAD; Joyce MG; Lakhal-Naouar I; Ahmed A; Cincotta CM; Subra C; Peachman KK; Hack HR; Chen RE; Thomas PV; Chen WH; Sankhala RS; Hajduczki A; Martinez EJ; Peterson CE; Chang WC; Choe M; Smith C; Headley JA; Elyard HA; Cook A; Anderson A; Wuertz KM; Dong M; Swafford I; Case JB; Currier JR; Lal KG; Amare MF; Dussupt V; Molnar S; Daye SP; Zeng X; Barkei EK; Alfson K; Staples HM; Carrion R; Krebs SJ; Paquin-Proulx D; Karasavvas N; Polonis VR; Jagodzinski LL; Vasan S; Scott PT; Huang Y; Nair MS; Ho DD; de Val N; Diamond MS; Lewis MG; Rao M; Matyas GR; Gromowski GD; Peel SA; Michael NL; Modjarrad K; Bolton DL
Proc Natl Acad Sci U S A; 2021 Sep; 118(38):. PubMed ID: 34470866
[TBL] [Abstract][Full Text] [Related]
14. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
[TBL] [Abstract][Full Text] [Related]
15. Pfizer COVID vaccine protects against worrying coronavirus variants.
Callaway E
Nature; 2021 May; 593(7859):325-326. PubMed ID: 33963317
[No Abstract] [Full Text] [Related]
16. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
17. Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models.
Li D; Luan N; Li J; Zhao H; Zhang Y; Long R; Jiang G; Fan S; Xu X; Cao H; Wang Y; Liao Y; Wang L; Liu L; Liu C; Li Q
Emerg Microbes Infect; 2021 Dec; 10(1):2194-2198. PubMed ID: 34736354
[TBL] [Abstract][Full Text] [Related]
18. Omicron likely to weaken COVID vaccine protection.
Callaway E
Nature; 2021 Dec; 600(7889):367-368. PubMed ID: 34880488
[No Abstract] [Full Text] [Related]
19. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
[TBL] [Abstract][Full Text] [Related]
20. Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice.
Turan RD; Tastan C; Dilek Kancagi D; Yurtsever B; Sir Karakus G; Ozer S; Abanuz S; Cakirsoy D; Tumentemur G; Demir S; Seyis U; Kuzay R; Elek M; Kocaoglu ME; Ertop G; Arbak S; Acikel Elmas M; Hemsinlioglu C; Hatirnaz Ng O; Akyoney S; Sahin I; Kayhan CK; Tokat F; Akpinar G; Kasap M; Kocagoz AS; Ozbek U; Telci D; Sahin F; Yalcin K; Ratip S; Ince U; Ovali E
Sci Rep; 2021 Aug; 11(1):15799. PubMed ID: 34349145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
